HOME >> MEDICINE >> NEWS
Enzyme halts muscle waste in mouse models of most-common childhood muscular dystrophy

The muscle destruction associated with Duchenne muscular dystrophy (DMD), the most common childhood form of muscular dystrophy, is halted in mice when supplemental amounts of a naturally occurring enzyme are added to the skeletal muscle.

These results from researchers at the University of California, San Diego (UCSD) School of Medicine are published in the April 16, 2002 issue of the journal Proceedings of the National Academy of Sciences.

Muscle wasting associated with DMD was inhibited after the UCSD team added an enzyme called CT GalNAc transferase to skeletal muscles in mice bred to develop DMD. Normally, CT GalNAc transferase is expressed in another area of the muscle, the neuromuscular junction, where nerves send impulses to muscle fiber. The UCSD team was able to re-position the enzyme so that it was available in the DMD-vulnerable skeletal muscle, which is the structural tissue that supports body movement.

We hope this enzyme can eventually be used as a therapy for Duchenne muscular dystrophy, said Paul Martin, Ph.D., UCSD assistant professor of neurosciences, a member of the UCSD Glycobiology Training and Research Center, and the studys senior author. It has the potential for managing the disease, much like we manage diabetes with insulin medication or injections.

The disease strikes one in 5,000 children, almost exclusively boys, before they reach the age of 6. DMD frequently leaves its victims wheelchair-bound by age 12 and most DMD children die in their early 20s. The disease is caused by a mutation in a protein called dystrophin, which helps anchor muscle fibers to the connective tissue surrounding them.

Losing dystrophin is like losing the foundation of your house, Martin said. Without that foundation, the house falls apart. Without dystrophin, muscles affected by DMD become damaged and break.

Martin discovered the enzyme as he looked for other proteins that might compensate for the disabled dystr
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
15-Apr-2002


Page: 1 2

Related medicine news :

1. Enzyme linked to mania and schizophrenia impairs higher brain functions
2. Enzyme prevents lung damage in premature infants
3. Enzyme found in blood vessels likely target to treat lung injury
4. Enzyme structure holds key to cocaine, heroin metabolism
5. Enzyme replacement therapy found to effectively treat patients with Fabry disease
6. Enzyme level linked to death after angioplasty
7. Enzyme could provide continual fat burning
8. NIH halts use of COX-2 inhibitor in large cancer prevention trial
9. Success of new treatment halts international blood pressure drug trial
10. Researchers identify brain protein that halts progression of Alzheimers
11. New oral medication halts blindness in AIDS patients

Post Your Comments:
(Date:3/2/2015)... March 02, 2015 Over the last ... among leading vendors seeking to expand their geographic presence ... is expected to reach $6.2 billion by 2019 at ... America including the U.S. and Canada and a major ... However developing regions such as Asia-Pacific including China and ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Regulatory ... focused on quality, regulatory and technical consulting, announces ... Chief Operating Officer. , Before joining RCA, ... leading R&D teams in all aspects of developing ... positions at Covidien (Medtronic), Regulatory Compliance Associates Inc., ...
Breaking Medicine News(10 mins):Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
Cached News: